ESC 365 - Fibroblast growth factor-23 is an independent predictor of hospitalization for heart failure and major cardiovascular adverse events in patients undergoing cardiac surgery

ESC Professional Premium Access

Fibroblast growth factor-23 is an independent predictor of hospitalization for heart failure and major cardiovascular adverse events in patients undergoing cardiac surgery

Session: Chronic heart failure - Prognosis and prediction of outcome

Topic: Biomarkers

Speaker: Doctor F. Hofer (Vienna, AT)

Event: ESC Congress 2022

Congress Presentation

Add to my library

About the speaker

Doctor Felix Hofer

Medical University of Vienna, Vienna (Austria)

0 follower

8 more presentations in this session

National Early Warning Score 2 provides independent prognostic information in patients hospitalized with heart failure with preserved ejection fraction

Speaker: Doctor K. Berge (Oslo, NO)

Introduction of a new scoring tool to identify clinically stable heart failure patients

Speaker: Mr A. Gingele (Maastricht, NL)

Prognostic value of liver damage assessed by direct bilirubin and skeletal muscle weakness in patients with heart failure

Speaker: Mr T. Noda (Sagamihara, JP)

A comprehensive study of the incremental prognostic value of novel biomarkers in PARADIGM-HF (Bio-PREDICT-HF)

Speaker: Doctor K. McDowell (Glasgow, GB)

Alkaline phosphatase and bilirubin combined are a powerful predictor of outcome in patients with heart failure and reduced ejection fraction: an analysis of the ATMOSPHERE and PARADIGM-HF trials

Speaker: Doctor C. Adamson (Glasgow, GB)

Access the full session

Chronic heart failure - Prognosis and prediction of outcome

Speakers: Doctor F. Hofer, Doctor K. Berge, Mr A. Gingele, Mr T. Noda, Doctor K. McDowell...

About the event

ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources